Press release - 24 May 2022
Largillière Finance is supporting BELILAB, a group of private medical biology laboratories based in the Pas-de-Calais region, in its merger with the BIOPATH Laboratoires group, thus consolidating its position as independent leader in the Hauts-de-France region.
BELILAB, which traces its origins back to 1945, operates four laboratories and a technical platform in Béthune, Pas-de-Calais - an arrangement that enables it to carry out analyses locally within short timeframes, and which will be maintained in the new group.
BIOPATH Laboratoires is the leading independent medical biology group in the Hauts-de-France region, with 46 sites organized around 10 technical and emergency platforms, 2 AMP* centers, and 46 medical biologists who see 8,000 patients/day, excluding COVID.
By joining forces with BIOPATH Laboratoires, BELILAB retains its structures and teams, and joins a group renowned for its innovative equipment, its ability to organize and adapt, particularly during the COVID crisis, and its proximity to patients and healthcare partners.
The combination of the BELILAB sites with those of BIOPATH Laboratoires will enable the new group to strengthen its geographical coverage and consolidate its position as leader in independent medical biology in the Hauts-de-France region, where the healthcare sector is consolidating strongly.
The sale process was led by Largillière Finance's teams, under an exclusive mandate from BELILAB's shareholders. At the end of a highly competitive process that attracted strong interest from several national and regional players, it was BIOPATH Laboratoires that finally convinced BELILAB's partners.
Shamir Razavhoussen, Associate Director at Largillière Finance, comments: “The health crisis has underlined, if proof were needed, the essential role of laboratories, which have to combine quality of analysis and service with geographical proximity, resulting in significant requirements in terms of equipment, investment in new technologies and support. Largillière Finance has developed solid expertise in the healthcare sector with several transactions to its credit, and masters the issues involved, which enabled us to fully meet the specifications set by our clients: to select and meet with a shortlist of candidates able to guarantee BELILAB the continuity of its teams, the human and technical resources to support its growth and development strategy, and the preservation of its corporate culture”.
Nicolas Jacob, biologist, BELILAB, adds: “We were impressed by Largillière Finance's involvement and its perfect command of the healthcare market.We chose BIOPATH Laboratoires for the convergence of our ideas and our human vision of medical biology, and for its ambitions in the Hauts-de-France region. We are delighted with this new step for BELILAB”.
Antoine Crinquette, Medical Biologist, Managing Director of the BIOPATH Laboratoires Group, concludes: “We are delighted to be joining forces with BELILAB, with whom we share the same values at the service of patients and healthcare partners, based on independence, responsibility, innovation and excellence. We would also like to thank the BELILAB teams for providing us with their expertise to support our common objective: to guarantee a high-quality, local healthcare offering, while consolidating the independence of medical biology.”
* Assisted reproduction
With offices in Paris, Lyon, Nantes, Brussels and Geneva, Largillière Finance is an independent investment bank dedicated to assisting managers and shareholders of small and medium-sized companies with their capital transactions: company sales and acquisitions, financing (capital and/or debt), financial engineering (valuation, etc.) and financial strategy.
